RTP Mobile Logo
One Year Later: The Practical Application of Research Advances in the Management of Early and Advanced Breast Cancer
Released April 2013

Featuring interviews with Drs Clifford Hudis and Kimberly L Blackwell. (Audio Content)

CE Disclosures and Faculty Information


    Breast cancer remains the most frequently diagnosed cancer in women, with an estimated 226,870 new cases and 39,510 deaths in the United States in 2012. Advances in screening and prevention have resulted in a steady down-stage migration at the time of disease presentation, such that only 5% of women have identifiable distant metastases at primary diagnosis and the number of individuals living with breast cancer has increased substantially, as has the population “at risk” for recurrent disease.

    The current clinical management of breast cancer is multidisciplinary and includes surgical resection of local disease with or without radiation therapy and the treatment of systemic disease (micro- or macroscopic) with cytotoxic chemotherapy, endocrine therapy, biologic therapy or combinations of these agents. The indication and utility of these local and systemic therapeutic options are based largely on a number of prognostic and predictive risk factors present within the patient or the tumor at the time of diagnosis. Despite the existence of various evidence- and/or consensus-based guidelines or algorithms that aim to assist oncologists in making treatment decisions, many areas of controversy persist within the academic and community settings. To bridge the gap between research and patient care, this audio program centered on the discussion of actual patients cared for in the community explores the application of emerging research data to the best-practice management of cases of early and advanced breast cancer. The goal of this CME activity is to help medical oncologists formulate up-to-date clinical management strategies.

    • Appropriately use biomarkers to assess risk and individualize therapeutic decision-making for patients with early breast cancer.
    • Implement a long-term clinical plan for the management of early and advanced HER2-positive breast cancer, incorporating existing and emerging targeted treatments.
    • Assimilate new clinical trial evidence into the therapeutic algorithm for localized and advanced ER-positive breast cancer.
    • Demonstrate knowledge of emerging research to support novel chemotherapeutic and nonchemotherapy-based regimens in the adjuvant and metastatic settings, and integrate these findings into best-practice disease-management strategies.
    • Recall the results of pivotal trials introducing effective new breast cancer therapeutics, and identify their current or potential impact on existing treatment algorithms.
    • Counsel appropriately selected patients about participation in ongoing breast cancer clinical research.
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity contains an audio component. The participant should listen to the audio MP3s.

    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
    FACULTYDr Hudis had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr BlackwellAdvisory Committee: Eisai Inc, Novartis Pharmaceuticals Corporation; Consulting Agreements: Novartis Pharmaceuticals Corporation, Xcenda; Speakers Bureau: Amgen Inc, Bristol-Myers Squibb Company, Genomic Health Inc, Novartis Pharmaceuticals Corporation.
    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.
    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Celgene Corporation, Eisai Inc, Genentech BioOncology and Genomic Health Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection  
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: April 2013
    Expiration date: April 2014

Acknowledge and close

Listen to audio:
One Year Later: The Practical Application of Research Advances in the Management of Early and Advanced Breast Cancer
Released April 2013

Featuring interviews with Drs Clifford Hudis and Kimberly L Blackwell. (Audio Content)

Read print: